BLOG / 🇮🇳 India / index intelligence · · daily

BSE Pharma Sector Regulatory Filings — October 26, 2026

India BSE PHARMA

By Gunpowder Editorial ·

4 high priority 11 medium priority 15 total filings analysed

Executive Summary

Across the 15 BSE Pharma constituent filings dated 2026-10-26, the dominant theme is an active earnings cycle: Mankind Pharma (the most heavily represented name with 8 filings) reported strong consolidated growth, with revenue up 17.3% YoY to INR 4,338 Cr, EBITDA up 27.2% to INR 1,175 Cr, and PAT up 37.7% to INR 716 Cr, while standalone revenue rose about 19% YoY to INR 3,145 Cr.

The growth is not uniform: Consumer Healthcare grew only 1.2% YoY and fell 7.0% QoQ, and consolidated employee costs and standalone other expenses grew faster than revenue, which tempers the margin story. Standalone finance costs fell sharply to INR 87.74 Cr from INR 149.22 Cr and total standalone borrowings declined from about INR 5,488 Cr to about INR 4,490 Cr in six months, signalling deleveraging. Peers Aurobindo, Abbott India, Pfizer, and Biocon have all announced Q2 FY27 board meetings clustered between November 3 and 5, 2026, with trading windows closed, so the main quantitative catalysts for the group fall in the next two weeks. Biocon's Yesintek licence expansion and Sun Pharma's INR 7,816 Cr NCD placement are the notable non-results developments. Mankind's pending amalgamations and the unresolved Section 132 income-tax dispute are the principal structural items to monitor.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: Corporate governance · M&A · Debt securities

Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from October 19, 2026.

Investment Signals (11)

  • Mankind Pharma ↓ (BULLISH)
    ▲

    Consolidated revenue +17.3% YoY to INR 4,338 Cr, EBITDA +27.2% to INR 1,175 Cr (margin +210 bps to 27.1%), PAT +37.7% to INR 716 Cr; H1 PAT +33.7% to INR 1,290 Cr

  • Mankind Pharma ↓ (BULLISH)
    ▲

    International revenue +32.7% YoY to INR 681 Cr, and anti-infectives recovered to 5.4% growth from 3.6% QoQ, showing diversified growth engines beyond domestic chronic

  • Mankind Pharma ↓ (BULLISH)
    ▲

    Standalone finance costs fell to INR 87.74 Cr from INR 149.22 Cr YoY and standalone borrowings dropped from about INR 5,488 Cr (Mar-26) to about INR 4,490 Cr (Sep-26), supporting bottom-line growth through deleveraging

  • Mankind Pharma ↓ (BULLISH)
    ▲

    Domestic ex-CH secondary sales grew 15.7% vs IPM 14.2%, a 1.1x outperformance in both chronic and acute segments

  • Mankind Pharma ↓ (BEARISH)
    ▲

    Consumer Healthcare revenue grew only 1.2% YoY to INR 229 Cr and declined 7.0% QoQ on softer category offtake in East and South India; OTC growth muted

  • Mankind Pharma ↓ (BEARISH)
    ▲

    Standalone other income fell to INR 58.83 Cr from INR 77.67 Cr YoY (six-month INR 92.79 Cr vs INR 142.88 Cr), so part of the profit growth is operating rather than treasury-driven

  • Mankind Pharma ↓ (BEARISH)
    ▲

    Consolidated employee benefits rose to INR 948.94 Cr from INR 825.18 Cr YoY (+15%), and standalone other expenses rose to INR 678.12 Cr from INR 610.45 Cr, growing faster than revenue and capping operating leverage

  • Mankind Pharma ↓ (BEARISH)
    ▲

    Q2 FY27 gross margin +90 bps YoY but -60 bps QoQ to 72.2%, with standalone inventory change swinging to a INR 3.19 Cr charge from INR (90.62) Cr in Q1

  • Biocon ↓ (BULLISH)
    ▲

    Janssen licence for Yesintek (Stelara biosimilar) extended to Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect, layering onto US/EU/UK/Canada/Japan rights; Stelara 2025 global sales $6.08 bn sizes the opportunity

  • Sun Pharmaceutical ↓ (BULLISH)
    ▲

    Completed INR 7,816 Cr unsecured NCD placement (Series A INR 2,003 Cr at 8.05% with put on 27-Mar-2028; Series B INR 5,813 Cr at 8.20%), greenshoe of INR 816 Cr exercised, fully subscribed base issue; indicates strong institutional demand for the credit

  • Sun Pharmaceutical ↓ (BEARISH)
    ▲

    Coupon of 8.05-8.20% on 5-year unsecured paper is relatively high for an AA-plus pharma issuer, which may signal a funding preference for long tenor over bank lines and warrants monitoring of the cost of debt

Risk Flags (8)

  • Mankind Pharma / Income Tax Dispute↓ [HIGH RISK]
    ▼

    Auditors issued an Emphasis of Matter on income-tax proceedings after a Section 132 search; INR 1,868.89 Cr of additions remain under appeal and INR 369.44 Cr of disallowances deleted in company's favour are still open to challenge by the tax department

  • Mankind Pharma / Consumer Healthcare↓ [MEDIUM RISK]
    ▼

    CH revenue -7.0% QoQ to INR 229 Cr and only +1.2% YoY; regional weakness in East and South India suggests the segment is losing momentum in a category where the company previously relied on steady offtake

  • Mankind Pharma / Consolidated Cost Structure↓ [MEDIUM RISK]
    ▼

    Employee benefits (+15% YoY) and other expenses outgrowing revenue (+17%) may erode the 210 bps EBITDA margin gain if top-line growth decelerates

  • Mankind Pharma / Other Income Decline↓ [MEDIUM RISK]
    ▼

    Standalone other income down roughly 24% YoY in Q2 and 35% in H1, reducing the non-operating cushion that supported earlier profit prints

  • Mankind Pharma / Inventory Build↓ [MEDIUM RISK]
    ▼

    Standalone changes in inventories flipped from a INR (90.62) Cr credit to a INR 3.19 Cr charge QoQ, a swing that could indicate working capital absorption or product-mix shifts worth probing on the call

  • Mankind Pharma / Corporate Restructuring Execution↓ [MEDIUM RISK]
    ▼

    Two intra-group amalgamations (Prolijune/Pavi Buildwell into parent; Upakarma Ayurveda into Mankind Consumer Products) require NCLT and statutory approvals, with appointed date April 1, 2027, plus a separate EUR 45M investment in Mankind Netherlands for a 70% stake in Armed Cell Therapeutics (ACTx), introducing execution and integration risk

  • Sun Pharmaceutical / Cost of Debt↓ [LOW RISK]
    ▼

    8.05-8.20% coupons on a 5-year unsecured issue signal that the group is paying a premium for long-dated, non-secured funding; if spreads widen or ratings shift, refinancing costs will rise

  • Biocon / Regulatory Gating↓ [LOW RISK]
    ▼

    All Yesintek commercial launches remain subject to regulatory approval in the newly licensed territories, so revenue timing is uncertain and the filing gives no financial quantification

Opportunities (8)

  • Mankind Pharma / Earnings Re-rating↓ (OPPORTUNITY)
    ◆

    Consolidated PAT +37.7% YoY and H1 PAT +33.7% outpace revenue (+17% Q2, +15% H1), indicating operating leverage that could support a higher multiple if sustained through Q3

  • Mankind Pharma / International Growth↓ (OPPORTUNITY)
    ◆

    International revenue +32.7% YoY to INR 681 Cr is the fastest-growing segment disclosed in the period and provides a diversification angle relative to domestic peers facing the same IPM dynamics

  • Mankind Pharma / Deleveraging Story↓ (OPPORTUNITY)
    ◆

    Standalone borrowings down about INR 1,000 Cr in six months and finance costs down 41% YoY give a clear capital-structure improvement narrative that could drive upgrades or incremental institutional ownership

  • Mankind Pharma / Anti-Infectives Recovery↓ (OPPORTUNITY)
    ◆

    Anti-infective growth accelerated to 5.4% from 3.6% QoQ, a sign of demand normalisation that could sustain domestic secondary-sales outperformance

  • Biocon / Stelara Biosimilar Expansion↓ (OPPORTUNITY)
    ◆

    Yesintek now licensed across US, EU, UK, Canada, Japan plus nine additional markets; with Stelara at $6.08 bn global sales, a successful multi-geography launch represents a meaningful revenue pool for a biosimilar franchise

  • Sun Pharmaceutical / Balance-Sheet Flexibility↓ (OPPORTUNITY)
    ◆

    Fully subscribed INR 7,816 Cr NCD raise with greenshoe exercised shows deep credit-market access and provides dry powder for growth or M&A without equity dilution

  • Mankind Pharma / Structural Simplification↓ (OPPORTUNITY)
    ◆

    Amalgamating wholly owned subsidiaries and folding Upakarma into Mankind Consumer Products reduces entity count and may improve capital allocation transparency once NCLT approves

  • Peer Earnings Set-up (Aurobindo, Abbott India, Pfizer, Biocon) (OPPORTUNITY)
    ◆

    Four index constituents report Q2 FY27 between Nov 3 and Nov 5; Mankind's strong +17% revenue growth and +27% EBITDA growth provides a benchmark for relative-performance trades into these prints

Sector Themes (6)

  • Quarterly Results Cluster in Early November (SECTOR THEME)
    ◆

    Aurobindo (Nov 4 board / Nov 5 call), Biocon (Nov 4 board and call), Abbott India (Nov 5 board) and Pfizer (Nov 3 board) all have trading windows closed until 1-2 days after results; the group's near-term data flow is concentrated in a 3-day window, creating event-driven volatility and a cross-read opportunity against Mankind's prints

  • Earnings Growth Outpacing Revenue in Leaders (SECTOR THEME)
    ◆

    Mankind's consolidated PAT (+37.7%) and EBITDA (+27.2%) growing faster than revenue (+17.3%) and standalone profit (+27%) vs revenue (+19%) shows that top-tier Indian pharma is delivering margin expansion, even as cost lines (employee and other expenses) grow faster than revenue in absolute terms

  • Domestic Chronic vs Consumer Health Divergence (SECTOR THEME)
    ◆

    Domestic ex-CH outperformed the IPM (15.7% vs 14.2%) while Consumer Healthcare stalled (+1.2% YoY, -7.0% QoQ), suggesting the branded-OTC and consumer categories are structurally softer than prescription chronic therapies; this divergence is relevant for peers with heavy OTC exposure

  • Balance-Sheet Repair and Refinancing (SECTOR THEME)
    ◆

    Mankind's standalone borrowings fell about 18% in six months and Sun Pharma raised INR 7,816 Cr of 5-year unsecured paper, indicating that the group has ample access to term funding and is actively managing its capital structure

  • Biosimilars and Licensing as Growth Vectors (SECTOR THEME)
    ◆

    Biocon's expanded Janssen licence and Mankind's EUR 45M ACTx investment in cell therapy both point to a continuing push beyond generics into biologics and advanced therapies, with regulatory approval timing as the gating factor

  • Tax Overhang Across Large Caps (SECTOR THEME)
    ◆

    Mankind's Section 132 search and pending appeals on INR 1,869 Cr of additions illustrate that tax-authority disputes remain a material but largely unquantified risk for large Indian pharma names, and warrant monitoring in peer disclosures

Watch List (7)

  • Pfizer Limited / Q2 FY27 Results↓
    👁

    Board meets Tuesday, November 3, 2026 with trading window closed until 48 hours after results; filing contains no financials, so the print is an open read on the Pfizer India franchise [Nov 3, 2026]

  • Aurobindo Pharma / Q2 FY27 Results and Interim Dividend↓
    👁

    Board meets November 4, 2026 to approve results and consider an FY27 interim dividend; earnings call on November 5 at 8:30 AM IST, with dividend declaration the key capital-allocation signal [Nov 4-5, 2026]

  • Biocon / Q2 FY27 Results and Yesintek Commentary↓
    👁

    Board meets November 4, 2026 with a 16:00 IST Zoom call; watch for Yesintek launch timing across newly licensed geographies and any update on US/EU biosimilar rollout [Nov 4, 2026]

  • Abbott India / Q2 FY27 Results↓
    👁

    Board meets Thursday, November 5, 2026, with trading window closed until November 7; results will provide a read on the Abbott India branded-generics franchise amid Mankind's consumer weakness [Nov 5, 2026]

  • Mankind Pharma / Consumer Healthcare Recovery and Tax Appeal↓
    👁

    Monitor whether management provides a CH recovery timeline on the Q2 call and whether the income-tax appeal on INR 1,869 Cr additions advances; the company's H1 print (already reported) and next quarter will be the test [Ongoing / Q3 FY27]

  • Mankind Pharma / Scheme of Arrangement Milestones↓
    👁

    NCLT filing and shareholder/creditor meetings for the Prolijune/Pavi Buildwell scheme (appointed date April 1, 2027) and Upakarma Ayurveda amalgamation; approvals are the next structural catalysts [Pending, 2026-2027]

  • Sun Pharmaceutical / NCD Investor Put Date↓
    👁

    Series A NCDs (INR 2,003 Cr) carry an investor put on 27 March 2028; any repricing or early redemption behaviour ahead of that date will signal credit-market sentiment toward the group [27 Mar 2028]

Filing Analyses (15)
Aurobindo Pharma Limited Corporate Governance neutral materiality 4/10

26-10-2026

Aurobindo Pharma has notified the exchanges under Regulation 29 of the SEBI LODR Regulations that its Board will meet on November 4, 2026 to approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and consider an interim dividend for FY 2026-27, if any. The company's trading window remains closed until November 6, 2026, reopening on November 7, 2026. The filing contains no quantitative financial results or dividend amounts.

  • · Board meeting date: Wednesday, November 4, 2026
  • · Trading window closed from October 1, 2026 until November 6, 2026; reopens November 7, 2026
  • · Exchange codes: NSE AUROPHARMA; BSE 524804
Mankind Pharma Limited Market Notice mixed materiality 7/10

26-10-2026

Mankind Pharma filed its investor presentation for Q2 and H1 FY27 results. Consolidated revenue from operations grew 17.3% YoY to INR 4,338 Cr in Q2 FY27 and EBITDA rose 27.2% YoY to INR 1,175 Cr, with EBITDA margin expanding 210 bps to 27.1%. However, Consumer Healthcare revenue declined 7.0% QoQ to INR 229 Cr amid softer category offtake, and OTC growth was muted, while International revenue grew 32.7% YoY to INR 681 Cr.

  • · Consumer Healthcare revenue declined 7.0% QoQ and was flagged as affected by slower category offtake and regional weakness in East and South India
  • · Secondary sales growth for Domestic ex-CH was 15.7% vs IPM 14.2%, a 1.1x outperformance; chronic outperformance was 1.1x and acute 1.1x
  • · Anti-infectives recovered QoQ to 5.4% growth in Q2 FY27 from 3.6% in Q1 FY27
  • · Operating cash flow was INR 814 Cr vs INR 723 Cr-equivalent comparison points; net debt to EBITDA improved to 0.6x and ROCE was 14% on a TTM basis
  • · International business grew 33% while OTC witnessed muted growth in the quarter
  • · Mankind has launched 1 new product in the US in Q2 FY27, bringing total US launches to 50
Abbott India Limited Corporate Governance neutral materiality 3/10

26-10-2026

Abbott India Limited has intimated BSE under Regulation 29(1)(a) of the SEBI LODR Regulations that its Board of Directors will meet on Thursday, November 5, 2026 to consider and approve unaudited financial results for the second quarter and half year ended September 30, 2026. The company also confirmed that its trading window for insiders remains closed from October 1, 2026 to November 7, 2026 (both days inclusive), pending the results announcement.

  • · Board meeting date: Thursday, November 5, 2026
  • · Trading window closure period: October 1, 2026 to November 7, 2026 (both days inclusive)
  • · Earlier trading window intimation was dated September 28, 2026
  • · Company scrip code on BSE: 500488
Pfizer Limited Corporate Governance neutral materiality 3/10

26-10-2026

Pfizer Limited has notified BSE and NSE that its Board of Directors will meet on Tuesday, November 3, 2026, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2026. The company also confirmed that the trading window for dealing in its shares will remain closed until 48 hours after the results are made public, in line with SEBI insider trading rules. The notice contains no financial figures, so no performance trend can be assessed from this filing.

  • · Board meeting scheduled for Tuesday, November 3, 2026
  • · Trading window remains closed until 48 hours after financial results are made public
  • · Filing made under Regulation 29 of SEBI (LODR) Regulations, 2015
Mankind Pharma Limited Analyst/Investor Meet neutral materiality 2/10

26-10-2026

Mankind Pharma Limited has filed an intimation that the audio recording of its Q2 and H1 FY27 earnings conference call, held on October 26, 2026, is now available via a link. The filing follows earlier intimations dated October 12, 2026 (scheduling) and October 22, 2026 (rescheduling) and contains no financial results, operating metrics, or guidance.

  • · Earnings call covered Q2 and H1 FY27 results; the filing itself does not disclose the financial figures discussed
  • · Filing made under SEBI LODR Regulations 30 and 51
  • · Scrip code 543904, symbol MANKIND
Biocon Limited Analyst/Investor Meet neutral materiality 3/10

26-10-2026

Biocon Limited has intimated to BSE and NSE that its Board of Directors will meet on November 4, 2026 to approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company has also scheduled an Earnings Conference Call for Analysts and Investors on the same day at 16:00 hrs IST over Zoom. The filing contains no financial performance figures; it is a logistical and procedural announcement.

  • · Trading window closed from October 1, 2026 to November 6, 2026 (both inclusive) and reopens November 7, 2026
  • · Audio recording of the call to be available before the next trading day or within 24 hours of call end, whichever is earlier; video within 48 hours
  • · Conference call transcript to be published within 5 working days of the call
  • · Call is over Zoom; participants asked to join 10 minutes before start
Biocon Limited Corporate Governance neutral materiality 4/10

26-10-2026

Biocon Limited has scheduled a Board Meeting on November 4, 2026 to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The trading window is closed from October 1, 2026 to November 6, 2026, reopening November 7, 2026. The company will also host a Q2 FY2026-27 earnings conference call for analysts and investors on November 4, 2026 at 16:00 hrs IST over Zoom.

  • · Trading window closed from Thursday, October 1, 2026 to Friday, November 6, 2026 (both inclusive); reopens Saturday, November 7, 2026
  • · Audio recording of the earnings call to be available before the next trading day or within 24 hours of call end, whichever is earlier; video within 48 hours
  • · Earnings call transcript to be published within 5 working days of the call on the company website
  • · Filing made under SEBI LODR Regulation 29(1) and the SEBI Prohibition of Insider Trading Regulations, 2015
  • · Scrip code BSE 532523; NSE symbol BIOCON
Mankind Pharma Limited Market Update mixed materiality 8/10

26-10-2026

Mankind Pharma reported standalone revenue from operations of ₹3,145.22 Cr for Q2 FY27 (quarter ended September 30, 2026), up from ₹2,636.95 Cr in the year-ago quarter, with standalone net profit of ₹581.95 Cr versus ₹459.80 Cr a year earlier. Consolidated revenue from operations rose to ₹4,337.86 Cr from ₹3,697.16 Cr, and consolidated profit for the period reached ₹716.12 Cr versus ₹520.18 Cr. Balanced view: standalone 'Changes in inventories' swung to a ₹3.19 Cr charge in the quarter from ₹(90.62) Cr in the immediately preceding quarter, standalone finance costs of ₹87.74 Cr fell from ₹149.22 Cr, while standalone Other income declined to ₹58.83 Cr from ₹77.67 Cr year-on-year, and standalone six-month Other income fell to ₹92.79 Cr from ₹142.88 Cr; the Board also approved an amalgamation of two wholly owned subsidiaries and additional investment of up to EUR 45M in Mankind Netherlands for acquiring a 70% stake in Armed Cell Therapeutics B.V. (ACTx).

  • · Standalone Other income declined to ₹58.83 Cr in Q2 FY27 from ₹77.67 Cr a year earlier, and six-month Other income fell to ₹92.79 Cr from ₹142.88 Cr
  • · Standalone Changes in inventories flipped to a ₹3.19 Cr charge in Q2 FY27 from ₹(90.62) Cr in Q1 FY27, with six-month changes at ₹(87.43) Cr
  • · Standalone Finance costs fell to ₹87.74 Cr in Q2 FY27 from ₹149.22 Cr in Q2 FY26, supporting profit growth
  • · Standalone trade receivables rose to ₹1,592.16 Cr from ₹1,163.63 Cr at March 31, 2026, and standalone net cash from operating activities for six months was ₹1,623.51 Cr
  • · Income tax assessment additions of ₹1,868.89 Cr remain under appeal, with ₹369.44 Cr of disallowances deleted by CIT(Appeals) subject to possible challenge before higher forums
  • · Board approved additional investment of up to EUR 45M in Mankind Netherlands, raising aggregate limit to EUR 50M, to acquire 70% of ACTx, a Belgian CAR-T cell therapy developer
  • · Balance-sheet cash rose sharply, with standalone cash and cash equivalents at ₹828.56 Cr versus ₹87.66 Cr at March 31, 2026; consolidated trade receivables rose to ₹2,179.31 Cr from ₹1,729.51 Cr
Mankind Pharma Limited Merger/Acquisition mixed materiality 7/10

26-10-2026

Mankind Pharma's Board, meeting on October 26, 2026, approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, and approved a Scheme of Arrangement amalgamating two wholly owned subsidiaries (Prolijune Lifesciences and Pavi Buildwell) into the parent with an appointed date of April 1, 2027. It also noted a separate amalgamation of Upakarma Ayurveda into Mankind Consumer Products, both step-down/wholly owned entities, pending statutory and NCLT approvals. Standalone revenue from operations for Q2 FY27 was ₹3,145.22 Crore, up 19.3% YoY from ₹2,636.95 Crore, while net profit rose to ₹581.95 Crore, though the auditors flagged an emphasis of matter on pending income tax proceedings.

  • · Scheme 1 is exempt from NOC requirement under Regulation 37(6) as an amalgamation of wholly owned subsidiaries with the holding company, but must be filed with exchanges for disclosure
  • · Scheme 1 requires approval from shareholders/creditors (as applicable), NCLT, and other authorities
  • · Auditors issued an emphasis of matter on income tax proceedings from a Section 132 search in an earlier year, with appeal pending before appellate tax authorities
  • · Prior-period standalone figures were restated for business combination accounting (Ind AS 103) related to the acquisition of the Bharat Serums and Vaccines business undertaking
  • · Q2 FY27 current tax rose to ₹148.74 Crore from ₹97.54 Crore, while the deferred tax expense swung to ₹52.90 Crore from a ₹(31.81) Crore credit
Mankind Pharma Limited Market Notice mixed materiality 7/10

26-10-2026

Mankind Pharma reported Q2 FY27 consolidated revenue from operations of INR 4,338 Crore, up 17.3% YoY, with EBITDA of INR 1,175 Crore (up 27.2% YoY) and PAT of INR 716 Crore (up 37.7% YoY). Domestic revenue was INR 3,657 Crore (up 14.8%), while Consumer Healthcare grew only 1.2% to INR 229 Crore and fell 7.0% QoQ, and OTC growth was muted in the quarter. H1 FY27 revenue reached INR 8,368 Crore (up 15.1%) with EBITDA of INR 2,235 Crore (up 26.0%) and PAT of INR 1,290 Crore (up 33.7%).

  • · Consumer Healthcare revenue grew only 1.2% YoY in Q2 FY27 and declined 7.0% QoQ, citing slower category offtake and regional impact in East and South India
  • · Q2 FY27 gross margin rose 90 bps YoY but fell 60 bps QoQ to 72.2%
  • · Anti-infectives recovered QoQ to 5.4% growth in Q2 FY27 from 3.6% in Q1 FY27
  • · International business grew 33% but OTC witnessed muted growth in Q2
  • · Mankind Domestic chronic outperformance of 1.1x excluding Tirzepatide; Cardiac grew 18.7% and Anti-diabetes 15.8%
  • · Secondary sales growth of 15.7% vs 14.2% IPM in Q2 FY27, representing 1.1x outperformance
  • · Diluted EPS of INR 17.2 in Q2 FY27 (up 38.9% YoY) and INR 30.9 in H1 FY27 (up 34.6% YoY), not annualised
  • · Market share: #1 rank for 9 years with 15.2% prescription share and 84.4% prescriber penetration in MAT Aug'26
  • · Earnings concall scheduled for 26 October 2026, 5:00 pm to 6:00 pm IST
Biocon Limited Market Update positive materiality 6/10

26-10-2026

Biocon Limited has signed a license agreement with Janssen Sciences Ireland enabling commercialization of Yesintek™, its proposed biosimilar to Stelara® (Ustekinumab), in Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea and Kazakhstan with immediate effect. This builds on previously announced Janssen agreements covering the United States, Europe, the UK, Canada and Japan. The filing discloses no financial amounts, revenue impact or deal consideration; the reference brand Stelara® had worldwide 2025 sales of $6.08 billion per Johnson & Johnson.

  • · Yesintek™ is a human interleukin-12 and -23 antagonist approved for Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
  • · Commercial launches in all countries remain subject to regulatory approval
Sun Pharmaceutical Industries Limited Debt Securities positive materiality 7/10

26-10-2026

Sun Pharmaceutical Industries Limited completed the private placement allotment of rated, listed, unsecured, redeemable non-convertible debentures (NCDs) with an aggregate face value of INR 7,816 crore on 26 October 2026, comprising Series A NCDs of INR 2,003 crore (8.05% p.a., put option on 27 March 2028) and Series B NCDs of INR 5,813 crore (8.20% p.a.). The base issue of INR 7,000 crore was fully subscribed and the company exercised a greenshoe option of INR 816 crore out of an available INR 3,000 crore. Both series mature on 27 October 2031.

  • · Series A NCDs carry a put option exercisable on 27 March 2028, allowing early redemption at par
  • · Series B NCDs are issued partly at a premium of INR 10 per debenture (issue price INR 1,00,010)
  • · Both series have a deemed allotment date of 26 October 2026 and scheduled redemption on 27 October 2031
  • · Debentures are unsecured and not backed by any charge over company assets
  • · Mandatory redemption may be triggered by specified events per the Key Information Document
  • · Series A coupon payments are semi-annual on 27 March and 27 October; Series B coupons are annual on 27 October
Aurobindo Pharma Limited Analyst/Investor Meet neutral materiality 2/10

26-10-2026

Aurobindo Pharma Limited has scheduled an analyst/investor earnings call for November 5, 2026 at 8:30 AM IST to discuss its unaudited financial results for the second quarter and half year ended September 30, 2026 (Q2FY27). The filing was made under Regulation 30(2) of the SEBI LODR Regulations, 2015, and was addressed to both NSE and BSE. No financial figures, performance metrics, or results are disclosed in this filing.

  • · Earnings call scheduled for Thursday, November 5, 2026 at 8:30 AM IST
  • · Call covers unaudited results for Q2FY27 and half year ended September 30, 2026
  • · Earnings presentation to be posted on the company website after results announcement
  • · Participants must pre-register via a Zoom link
Mankind Pharma Limited Corporate Governance mixed materiality 7/10

26-10-2026

Mankind Pharma reported standalone revenue from operations of ₹3,145.22 Cr for Q2 FY27 (quarter ended September 30, 2026), up from ₹2,636.95 Cr a year earlier, and standalone PAT of ₹581.95 Cr versus ₹459.80 Cr, though sequentially revenue rose from ₹2,964.05 Cr. On a consolidated basis, revenue from operations was ₹4,337.86 Cr versus ₹3,697.16 Cr, and PAT was ₹716.12 Cr versus ₹520.18 Cr. Basic standalone EPS was ₹14.09 versus ₹11.15. Mixed signals remain: total borrowings declined on the balance sheet, but other expenses and employee costs grew faster than the top line in the period, and an income-tax dispute involving ₹1,868.89 Cr of additions remains under appeal, with ₹369.44 Cr of disallowances deleted in favour of the company but still open to challenge by the tax department.

  • · Standalone total borrowings (current and non-current) fell from roughly ₹5,488 Cr at March 31, 2026 to roughly ₹4,490 Cr at September 30, 2026
  • · Consolidated employee benefits expense rose to ₹948.94 Cr in Q2 FY27 from ₹825.18 Cr a year earlier, growing faster than consolidated revenue
  • · Standalone other expenses rose to ₹678.12 Cr in Q2 FY27 from ₹610.45 Cr a year earlier
  • · Standalone trade receivables increased to ₹1,592.16 Cr from ₹1,163.63 Cr at March 31, 2026
  • · Company intends to incorporate a Netherlands SPV for niche therapy R&D and approved an increase in the Netherlands investment limit to EUR 50 Mn
  • · Standalone results include a ₹19.02 Cr stamp duty charge treated as an exceptional item on the BSV IP assignment
Mankind Pharma Limited Merger/Acquisition mixed materiality 8/10

26-10-2026

Mankind Pharma's Board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, reporting standalone revenue from operations of ₹3,145.22 Cr for the quarter (up from ₹2,636.95 Cr in Q2 FY26, roughly 19% YoY) and standalone profit for the period of ₹581.95 Cr, up about 27% YoY. The Board also approved a scheme of amalgamation merging two wholly owned subsidiaries, Prolijune Lifesciences and Pavi Buildwell, into the parent with an appointed date of April 1, 2027, and took note of a second scheme merging Upakarma Ayurveda into Mankind Consumer Products. However, standalone finance costs fell to ₹87.74 Cr from ₹149.22 Cr YoY, while other comprehensive income and the Emphasis of Matter on pending income tax proceedings remain points of caution.

  • · Scheme 1 appointed date is April 1, 2027 and requires NCLT approval, shareholder/creditor approval as may be required, and other statutory approvals; it is exempt from the stock exchange No-Objection Letter under Regulation 37(6) and is filed for disclosure only
  • · Scheme 2 remains subject to statutory and regulatory approvals and was approved by the subsidiaries' boards on October 26, 2026
  • · Auditors include an Emphasis of Matter on income tax proceedings following a Section 132 search, with an appeal pending before appellate tax authorities; the conclusion is not modified
  • · Prior-period comparatives for Sept 2025 were restated for the business combination (acquisition of the Bharat Serums and Vaccines Limited undertaking) under Ind AS 103
  • · Standalone six-month revenue from operations was ₹6,109.27 Cr versus ₹5,206.68 Cr a year earlier, roughly 17% growth
  • · Standalone profit for the six months ended Sept 30, 2026 was ₹1,140.44 Cr versus ₹875.07 Cr, roughly 30% growth
  • · Standalone basic EPS for the quarter was ₹14.09 versus ₹11.15 a year earlier, while standalone other income declined about 24% YoY

Get daily alerts with 11 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 15 filings

Start free trial Browse all digests

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE Pharma Sector Regulatory Filings

October 16, 2026

BSE Pharma Sector Regulatory Filings — October 16, 2026

October 15, 2026

BSE Pharma Sector Regulatory Filings — October 15, 2026

October 14, 2026

BSE Pharma Sector Regulatory Filings — October 14, 2026

October 13, 2026

BSE Pharma Sector Regulatory Filings — October 13, 2026

🇮🇳 More from India

View all →

October 19, 2026

India Quarterly Results BSE NSE Announcements — October 19, 2026

India Quarterly Results BSE NSE Announcements

October 19, 2026

India Pre-Market Regulatory Roundup — October 19, 2026

India Pre-Market Regulatory Roundup

October 19, 2026

India Upcoming Corporate Actions BSE NSE — October 19, 2026

India Upcoming Corporate Actions BSE NSE

October 19, 2026

BSE Sensex 30 Stocks Regulatory Filings — October 19, 2026

BSE Sensex 30 Stocks Regulatory Filings
← All India digests